Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

Neurology. 2001 Jan 9;56(1):97-9. doi: 10.1212/wnl.56.1.97.

Abstract

In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Middle Aged
  • Myasthenia Gravis / drug therapy*
  • Mycophenolic Acid / administration & dosage*
  • Mycophenolic Acid / analogs & derivatives
  • Pilot Projects
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid